Physician profile
Brandy Stufft
NPI 1104304583
$2,596.26
in general payments reported to CMS, 2019-2025
24 companies · $621 in 2025
The $621 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $34.88 · 2022: $476 · 2023: $684 · 2024: $780 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,085.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $480.87 | 2022-2025 | |
| Abbvie INC. | $434.58 | 2022-2025 | |
| Lilly USA, LLC | $329.63 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $235.06 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $185.23 | 2022-2024 | Xifaxan, Trulance |
| Novo Nordisk INC | $175.27 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $102.76 | 2022-2025 | Trelegy Ellipta |
| Astellas Pharma US INC | $79.61 | 2023-2025 | Veozah |
| Exact Sciences Corporation | $75.96 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $75.11 | 2021-2025 | Verquvo, Steglatro, Enflonsia |
| Amgen INC. | $65.88 | 2022-2025 | Repatha, Evenity, Otezla |
| Biohaven Pharmaceutical Holding Company Ltd. | $54.21 | 2022 | |
| Phathom Pharmaceuticals, INC. | $46.51 | 2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $45.85 | 2022-2023 | |
| Dynavax Technologies Corporation | $33.65 | 2023-2024 | Heplisav-B |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $32.51 | 2023-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.81 | 2023 | Jardiance, Tradjenta |
| Axsome Therapeutics, INC. | $21.13 | 2025 | Auvelity |
| Inspire Medical Systems, INC. | $19.36 | 2024 | Inspire |
| Abbott Laboratories | $17.17 | 2025 | Freestyle Libre 3 |
| Lundbeck LLC | $16.05 | 2025 | Rexulti |
| Amarin Pharma, INC. | $15.88 | 2022 | |
| Azurity Pharmaceuticals, INC. | $13.60 | 2025 | |
| Xeris Pharmaceuticals, INC. | $13.57 | 2025 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandy Stufft listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.